drugset / Trial / NCT03219671
Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS)
NaSingle-groupOpen-labelTreatment
Summary
A Phase 2 study of nivolumab plus ipilimumab in previously treated classical Kaposi Sarcoma (CKS)
Timeline
- Start
- 2018-04-01
- Primary completion
- 2020-09-01
- Completion
- 2022-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | 1 mg/kg | — |
| Subject | Nivolumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |